AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2251993
Drug: Anticoagulants (heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulants (heparin followed by phenprocoumon)
Trial: 26418274
Drug: Intravenous ghrelin
RxNorm normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ghrelin administration
Trial: 19617841
Drug: Leg wrapping
RxNorm normalized name: Crab leg
DrugBank: Crab leg (DB11011)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leg wrapping with tight elastic bandage plus placebo intravenous injections
Trial: 17179052
Drug: Agalsidase beta
RxNorm normalized name: Agalsidase beta
DrugBank: Agalsidase beta (DB00103)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Agalsidase beta (1 mg per kg of body weight) every 2 weeks for up to 35 months (median, 18.5 months)
Trial: 17179052
Drug: Agalsidase beta
RxNorm normalized name: Agalsidase beta
DrugBank: Agalsidase beta (DB00103)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Agalsidase beta (1 mg per kg of body weight) in protocol-adherent patients
Trial: 17179052
Drug: Agalsidase beta
RxNorm normalized name: Agalsidase beta
DrugBank: Agalsidase beta (DB00103)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Agalsidase beta (1 mg per kg of body weight) in patients with baseline eGFR > 55 mL/min per 1.73 m2
Trial: 17179052
Drug: Agalsidase beta
RxNorm normalized name: Agalsidase beta
DrugBank: Agalsidase beta (DB00103)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Agalsidase beta (1 mg per kg of body weight) in patients with baseline eGFR ≤ 55 mL/min per 1.73 m2
Trial: 11531899
Drug: Alniditan 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alniditan 1.8 mg
Trial: 9471290
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream (lidocaine and prilocaine) applied before laser treatment
Trial: 8509530
Drug: Single-stage tilt
RxNorm normalized name: SAGE
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-stage tilt test with an infusion of 5 micrograms/min of isoproterenol
Trial: 8509530
Drug: Multistage tilt
RxNorm normalized name: TILT-123
DrugBank: TILT-123 (DB17519)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multistage tilt test with infusions of 0, 2 and 5 micrograms/min of isoproterenol
Trial: 3543769
Drug: Mezlocillin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mezlocillin (4 g intravenously before surgery, second dose 4-6 hours later, final dose 6 hours after)
Trial: 3543769
Drug: Placebo (saline,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline, same dosing schedule as mezlocillin)
Trial: 23787458
Drug: Corneal collagen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corneal collagen crosslinking (CXL) treatment
Trial: 21490140
Drug: DHA-rich fish-oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-rich fish-oil capsules (≈800 mg DHA/d)
Trial: 21490140
Drug: Vegetable oil
RxNorm normalized name: Vegetable Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vegetable oil capsules (control group)
Trial: 10761206
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (isosorbide‐5‐mononitrate and propranolol or nadolol)
Trial: 10761206
Drug: Endoscopic injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic injection sclerotherapy and endoscopic banding ligation
Trial: 10761206
Drug: Pharmacological therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological therapy followed by semi‐emergency endoscopic therapy
Trial: 8383415
Drug: 18 mg
RxNorm normalized name: niacin 18 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 mg iron daily
Trial: 2463726
Drug: Acetated Ringer
RxNorm normalized name: ACETATED RINGER'S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetated Ringer solution (n = 45)
Trial: 27692023
Drug: Red wine
RxNorm normalized name: Red wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red wine (150 ml with dinner)
Trial: 27692023
Drug: Mineral water
RxNorm normalized name: mineral water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mineral water (150 ml with dinner)
Trial: 25313213
Drug: Rifampin Cmax
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin Cmax >8.2 mg/liter
Trial: 25313213
Drug: Rifampin AUC
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin AUC <35.4 mg · h/liter
Trial: 12772396
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba 100 mg daily
Trial: 12772396
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 100 mg daily
Trial: 9292184
Drug: Budesonide 128
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide 128 micrograms once daily
Trial: 9292184
Drug: Budesonide 256
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide 256 micrograms once daily
Trial: 3533454
Drug: Propafenone high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone high dosage (300 mg every eight hours)
Trial: 3533454
Drug: Propafenone low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone low dosage (150 mg every eight hours)
Trial: 28410250
Drug: Antigravity treadmill
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antigravity treadmill training (20 mins/d, 3 d/wk) together with traditional physical therapy for 3 months
Trial: 27715335
Drug: Indacaterol/Glycopyrronium (IND/GLY)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indacaterol/Glycopyrronium (IND/GLY) 110/50 μg once daily
Trial: 24255993
Drug: 1‐h ultrasonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1‐h ultrasonic debridement with frequent oral hygiene reinforcement (OHI) over four visits
Trial: 24255993
Drug: 1‐h ultrasonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1‐h ultrasonic debridement without frequent oral hygiene reinforcement (control)
Trial: 19653573
Drug: Modafinil plus
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Modafinil plus oral scopolamine (MS)
Trial: 17595750
Drug: Ranolazine in
RxNorm normalized name: Product containing ranolazine in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranolazine in combination with standard anti-anginal medications
Trial: 17595750
Drug: Standard anti-anginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard anti-anginal medications only
Trial: 17595750
Drug: Ranolazine added
RxNorm normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranolazine added to standard treatment
Trial: 10215735
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate (RBC) 400 mg b.d., metronidazole 500 mg b.d., clarithromycin 500 mg b.d. for 1 week
Trial: 7474331
Drug: Azithromycin (AZM)
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin (AZM) 500 mg once daily for 3 days
Trial: 2081275
Drug: Bestatin 60
RxNorm normalized name: Nystatin
DrugBank: Nystatin (DB00646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bestatin 60 mg a day
Trial: 7426081
Drug: Combined regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined regimen of nicotinic acid (up to 3 g daily) and 2 g of clofibrate daily
Trial: 28716236
Drug: Hypoglycemic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoglycemic treatment during hospitalization
Trial: 28716236
Drug: No hypoglycemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No hypoglycemic treatment during hospitalization
Trial: 17564649
Drug: Oral clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clonidine 4 µg/kg
Trial: 17564649
Drug: Transmucosal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transmucosal dexmedetomidine 1 µg/kg
Trial: 15151094
Drug: Neodolpasse (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neodolpasse (75 mg diclofenac and 30 mg orphenadine)
Trial: 9486756
Drug: New SSRIs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New SSRIs (fluvoxamine, paroxetine, sertraline)
Trial: 9486756
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (nonteratogenic agents)
Trial: 26380439
Drug: Compound Tongtu
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Tongtu Granule (CTG), 14.3 g per package, twice daily for 14 days
Trial: 26380439
Drug: Placebo, 14.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 14.3 g per package, twice daily for 14 days
Trial: 16722029
Drug: New bicarbonate/lactate-buffered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New bicarbonate/lactate-buffered solution (N)
Trial: 9247776
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg elemental iron (Polysaccharide complex, Central Pharmaceuticals), twice daily for 3 months
Trial: 1656730
Drug: Alpha 1-antagonist
RxNorm normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha 1-antagonist (prazosin)
Trial: 7664425
Drug: Alpha 2-antagonist
RxNorm normalized name: Alpha-adrenoreceptor antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha 2-antagonist (yohimbine)
Trial: 7664425
Drug: Both alpha
RxNorm normalized name: alpha tocopherol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both alpha 1 and alpha 2 antagonists
Trial: 23824662
Drug: neostigmine 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neostigmine 50 μg/kg/glycopyrrolate 10 μg/kg
Trial: 21832216
Drug: Extended-release pramipexole
RxNorm normalized name: pramipexole Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release pramipexole (0.375-4.5 mg/day)
Trial: 21832216
Drug: Immediate-release pramipexole
RxNorm normalized name: pramipexole Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release pramipexole (3 times daily)
Trial: 17078576
Drug: Tadalafil 20
RxNorm normalized name: tadalafil 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 20 mg administered 3 times/week (SCH)
Trial: 17078576
Drug: Tadalafil 20
RxNorm normalized name: tadalafil 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 20 mg on demand (OD)
Trial: 1895958
Drug: Somatostatin infusion
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin infusion (SRIF, 500 micrograms/h)
Trial: 1895958
Drug: SRIF infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRIF infusion preceded by a nicotinic acid analogue (acipimox, 250 mg orally)
Trial: 1895958
Drug: SRIF plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRIF plus insulin infusion
Trial: 1895958
Drug: SRIF plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRIF plus insulin plus intralipid infusion
Trial: 1895958
Drug: SRIF plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRIF plus insulin infusion plus acipimox
Trial: 6628507
Drug: triamterene 10
RxNorm normalized name: triamterene 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: triamterene 10 mg i.v.
Trial: 6628507
Drug: triamterene 50
RxNorm normalized name: triamterene 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: triamterene 50 mg p.o.
Trial: 19940820
Drug: Paravertebral block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paravertebral block (PVB) with 5 mL of 0.5% levobupivacaine at T9-L1 levels
Trial: 19940820
Drug: Spinal anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anesthesia (SA) with 8 mg of 0.5% hyperbaric levobupivacaine at L2-L3 level
Trial: 17633796
Drug: Spironolactone (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (group A) at a mean dose of 37.5 mg once a day (n = 14)
Trial: 15122957
Drug: Dehydroepiandrosterone (DHEA;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dehydroepiandrosterone (DHEA; 100 mg/day)
Trial: 9667268
Drug: Myeloablative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myeloablative chemotherapy with autologous bone marrow rescue (ABMR)
Trial: 9667268
Drug: Myeloablative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myeloablative chemotherapy with ABMR followed by external-beam irradiation
Trial: 7713852
Drug: Immediate switch
RxNorm normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate switch to 20 mg of paroxetine daily after last dose of fluoxetine (N = 123)
Trial: 7713852
Drug: Placebo-washout followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-washout followed by 20 mg of paroxetine daily (N = 119)
Trial: 1693474
Drug: Heparin (postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (postoperative treatment for all patients)
Trial: 24114718
Drug: Start For
RxNorm normalized name: Star Anise Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Start For Life treatment (30 min per day)
Trial: 17357049
Drug: Intranasal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal administration of citrate/phosphate (CP) buffer
Trial: 11176554
Drug: Inpatient programs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient programs that converted to residential treatment
Trial: 11176554
Drug: Residential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Residential treatment programs established before the period of change
Trial: 9141935
Drug: LA‐IVRA (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LA‐IVRA (90 mg of lysine acetylsalicylate mixed with prilocaine 0.5%)
Trial: 9141935
Drug: LA‐IV (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LA‐IV (1 mL of 0.9% NaCl mixed with prilocaine and 90 mg of LA administered IV)
Trial: 9141935
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 mL of 0.9% NaCl administered with prilocaine for IVRA and IV)
Trial: 2880687
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg acetaminophen (single dose) with 100 mg fenoldopam
Trial: 2880687
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg acetaminophen (chronic dosing for 7 days) with 100 mg fenoldopam
Trial: 2880687
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg fenoldopam alone
Trial: 2880687
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg fenoldopam with 1000 mg acetaminophen
Trial: 22147680
Drug: 6RM training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6RM training protocol (3 sets of 6RM, twice per week for 8 weeks)
Trial: 22147680
Drug: 12RM training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12RM training protocol (3 sets of 12RM, twice per week for 8 weeks)
Trial: 19637942
Drug: Long-acting beta(2)-agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting beta(2)-agonists
Trial: 19637942
Drug: Combination inhaled
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination inhaled corticosteroid-long-acting beta(2)-agonist therapy
Trial: 19637942
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy vs Tiotropium
Trial: 8273807
Drug: Indomethacin 50
RxNorm normalized name: indomethacin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 50 mg P.O. t.i.d. for 3 consecutive days
Trial: 2510260
Drug: Rioprostil 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rioprostil 600 micrograms once-daily orally
Trial: 2510260
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg once-daily orally
Trial: 31905307
Drug: M‐ACT (multimodal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M‐ACT (multimodal acceptance and commitment therapy)
Trial: 30187159
Drug: Fluoxetine (n=15)
RxNorm normalized name: fluoxetine 15 MG
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine (n=15)
Trial: 17702132
Drug: Post-surgical adjuvant
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-surgical adjuvant chemotherapy
Trial: 17702132
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy or chemotherapy with subsequent surgery
Trial: 2757939
Drug: UVA sunbeds
RxNorm normalized name: UVA URSI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UVA sunbeds (3 times weekly for 4 weeks)
Trial: 2757939
Drug: Visible light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visible light sunbeds (3 times weekly for 4 weeks)
Trial: 359779
Drug: Oral codeine
RxNorm normalized name: codeine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral codeine
Trial: 25376453
Drug: Any fertility
RxNorm normalized name: Tests for fertility disturbances
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any fertility drug
Trial: 11511297
Drug: Ultraviolet irradiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultraviolet irradiation (2 minimal erythema doses)
Trial: 10205771
Drug: Acetaminophen (APAP)
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (APAP) 12.5 mg/kg
Trial: 10205771
Drug: Ibuprofen (IBU)
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen (IBU) 5 mg/kg
Trial: 10205771
Drug: Ibuprofen (IBU)
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen (IBU) 10 mg/kg
Trial: 2787232
Drug: Small-dose, frequent-injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small-dose, frequent-injection group (injection volumes of less than 10 cc at mean intervals of three days)
Trial: 2787232
Drug: Large-dose weekly
RxNorm normalized name: Bos taurus large intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large-dose weekly treatment group (injection volumes greater than 15 cc at weekly intervals)
Trial: 2787232
Drug: Small-dose, frequent-injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small-dose, frequent-injection group
Trial: 5090826
Drug: Betamethasone 17-valerate
RxNorm normalized name: Cortisol 17-valerate
DrugBank: Hydrocortisone valerate (DB14544)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone 17-valerate (5 mg) retention enema
Trial: 5090826
Drug: Prednisolone 21-phosphate
RxNorm normalized name: Prednisolone 21-phosphate
DrugBank: Prednisolone phosphate (DB14631)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 21-phosphate (20 mg) retention enema
Trial: 23238444
Drug: Bilateral injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral injection of 2.5-3.75 U BTA combined with sodium hyaluronate (SH) to the medial rectus muscle.
Trial: 23238444
Drug: Bilateral injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral injection of 2.5-3.75 U BTA solution alone to the medial rectus muscle.
Trial: 19732191
Drug: Atraumatic restorative
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atraumatic restorative treatment (ART) restorations with cavity size between 2 and 3 mm or volumes 10.0-19.9 mm(3)
Trial: 16997837
Drug: 0.6 mg
RxNorm normalized name: thymol 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg kg(‐1) rocuronium
Trial: 15160663
Drug: Colforsin (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colforsin (0.25 to 0.5 microg x kg(‐1) x min(‐1) loading dosage increased every 60 minutes)
Trial: 9051366
Drug: Acarbose (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose (50 to 300 mg t.i.d.)
Trial: 3524065
Drug: Acemethacin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acemethacin (60 mg t.i.d.)
Trial: 3524065
Drug: Proglumethacin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proglumethacin (150 mg t.i.d.)
Trial: 29355982
Drug: iPad applications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iPad applications requiring specific motor skills, used for 30 minutes daily for 9 weeks
Trial: 25358225
Drug: ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron 4 mg with dexamethasone 8 mg